Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNA3 | P22001 | 10/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | PKM | P14618 | 1/20 | 0.37 |
| ▸ | RAB9A | P51151 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
| ▸ | NCOA3 | Q9Y6Q9 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12597489 | 0.85 | RARA (0.40) | SMN1; SMN2KDM4EALDH1A1HPGD | |
| SCHEMBL9479581 | 0.81 | GAA (0.39) | KCNA3KDM4EALDH1A1HPGDMAPT | |
| SCHEMBL16844527 | 0.80 | KCNA3 (0.40) | KCNA3 | |
| SCHEMBL16844587 | 0.80 | KCNA3 (0.40) | KCNA3KDM4EALDH1A1HPGDMAPT | |
| SCHEMBL12126790 | 0.78 | TSHR (0.47) | POLBKDM4EALDH1A1HPGDMAPT | |
| SCHEMBL21951041 | 0.77 | KCNA3 (0.38) | KCNA3KDM4EALDH1A1HPGDMAPT | |
| SCHEMBL31120928 | 0.75 | CYP1A2 (0.39) | KCNA3POLBSMN1; SMN2KDM4EALDH1A1 | |
| SCHEMBL806473 | 0.75 | CYP1A2 (0.39) | KCNA3POLBSMN1; SMN2KDM4EALDH1A1 | |
| SCHEMBL30911911 | 0.73 | KCNA3 (0.40) | KCNA3POLBMAPTCREBBP | |
| SCHEMBL21950946 | 0.73 | KCNA3 (0.40) | KCNA3RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160311791-A1 | NOVEL TRICYCLIC CALCIUM SENSING RECEPTOR ANTOGONISTS FOR THE TREATMENT OF OSTEOPOSOSIS | MERCK SHARP & DOHME CORP. (US) | 2016-10-27 | — | — | US | disclosed |
| WO-2015089842-A1 | NOVEL TRICYCLIC CALCIUM SENSING RECEPTOR ANTAGONISTS FOR THE TREATMENT OF OSTEOPOROSIS | MERCK SHARP & DOHME CORP. (US) | 2015-06-25 | — | — | WO | disclosed |
| WO-2015095261-A1 | NOVEL TRICYCLIC CALCIUM SENSING RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME CORP. (US) | 2015-06-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160311791-A1 | NOVEL TRICYCLIC CALCIUM SENSING RECEPTOR ANTOGONISTS FOR THE TREATMENT OF OSTEOPOSOSIS | CASR, CALCR, CALCRL | KCNA3 1934/4885NPC1 1971/4885POLB 4847/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.